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a b s t r a c t
Sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of renal cell carcinoma (RCC) that has a
signiﬁcantly lower overall survival. Even after prompt surgical extirpation, this histologic variant pro-
gresses rapidly. We present a case of an early recurrence and rapid progression of sRCC despite successful
radical resection.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Renal cell carcinoma (RCC) is the most prevalent kidney cancer
and approximately 14,000 patients will succumb to this disease
each year.1 Sarcomatoid renal cell carcinoma (sRCC) is rare, with an
incidence of 4e32% based on contemporary studies, and is a
potentially fatal differentiation of RCC.2 This diagnosis is signiﬁcant
because sRCC conveys a worse survival compared to other RCC
subtypes. The overall survival (OS) for patients with sRCC can be as
little as 4 months.3 We present a case of sRCC that recurred rapidly
in the nephrectomy bed despite negative margins in the pathology
specimen.
2. Case presentation
A seventy-two year old female with a history of gastroesopha-
geal reﬂux disease and osteoarthritis presented to her primary
physician with left abdominal pain. She was found to have a large
left renal mass and was subsequently referred to urology for
management. The renal mass measured 14 cm (Fig. 1). The extent of
disease workup, which included bone scan and chest x-ray, were
negative.
She underwent a left radical nephrectomy via a thor-
acoabdominal approach. Final pathology demonstrated a 14.3 cm
RCC with sarcomatoid differentiation with negative surgical mar-
gins (Fig. 2).
On postoperative day 46, the patient presented to the emer-
gency room with severe left sided ﬂank pain, characteristic of her
presentation preoperatively. Her exam was unremarkable for signs
concerning for wound complications or gastrointestinal pathology.
Serologic testing was unremarkable for anemia, inﬂammation, or
electrolyte abnormalities. Computed tomography demonstrated a
10.6 cm mass which was indeterminate for tumor or organized
hematoma. An MRI was performed showing that the mass was
indeed solid and consistent with local tumor recurrence (Fig. 3). A
core needle biopsy conﬁrmed the diagnosis of recurrent sRCC.
Oncologywas consulted for her rapidly recurrent cancer. Additional
molecular testing was perform to identify immunotherapy targets
however none was found.
Despite adjuvant therapy with gemcitabine and sunitinib, the
cancer progressed rapidly with an average growth rate of 0.3 mm
per day during her hospital stay to a maximum 21.5 cm on
postoperative day 80 as demonstrated on serial axial imaging
studies (Table 1). The family elected to pursue comfort measures
given her poor response to treatment. She was discharged to
home hospice care and succumbed to her cancer on post op day
114.
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3. Discussion
In summary, a seventy-two year old female underwent a left
radical nephrectomy for a 14 cm renal cell carcinoma with sarco-
matoid features which rapidly recurred in just 46 days. Despite an
oncologically successful operation, the tumor recurred because of
its high potential to seed the abdominal cavity. A recent series
examined radiologic and pathologic features of abdominal seeding
in patients with RCC.4 In 10 years, they found 25 cases of abdominal
seeding in 2561 pathologically conﬁrmed RCC cases. Despite this
small cohort, nearly one-third of these patients had sRCC, a rather
high proportion given the fact that abdominal seeding is an un-
common event in conventional RCC. Of note, only one patient had a
positive surgical margin. In a recent series of patients with sRCC,
Keskin et al. reported clinical ﬁndings similar to our case with pain
being the most common presenting symptom (52.3%) and large
tumor size at presentation (median ¼ 11 cm, range 1.8e27). The
aggressive nature of sRCC was also seen in this series with 30.1%
developing metastases following radical nephrectomy. Of 199 pa-
tients, Keskin et al. reported 167 succumbed with median OS being
16.5 months (94% at six months, 67% at 12 months, 38% at two
years,14% at ﬁve years).3 Chemotherapy did not improve OS in their
cohort however, there was a trend towards improved survival in
the era of targeted therapy. Recently, a phase III randomized,
double-blind, placebo controlled trial with adjuvant sunitinib was
reported by Ravaud and colleagues.5 Although this study did not
examine sarcomatoid differentiated tumors speciﬁcally, the cohort
involved patients with high risk clear cell carcinoma. 309 patients
were assigned to sunitinib and 306 patients received placebodin
the sunitinib group, the median disease-free survival was 6.8 years
versus placebo which was 5.6 years.5 Sunitinib increased overall
survival compared to placebo by one year; however, this was not
statistically signiﬁcant. We hope that advancements in targeted
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Fig. 1. Preoperative CT abdomen and pelvis with contrast. A 14 cm enhancing left renal
mass. Top axial view, Bottom coronal view.
Fig. 2. Histologic slide from the resected renal mass. Sarcomatoid component with
pleomorphic spindle cells with numerous mitotic ﬁgures is seen in this specimen.
Fig. 3. MRI abdomen with contrasting. Tumor recurrence is seen within the left renal
fossa measuring almost the same size as the original tumor.
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therapies will be made in order to improve outcomes of patients
with this devastating variant of RCC.
4. Conclusion
RCC with sarcomatoid differentiation is a rapidly progressive
form of kidney cancer that requires prompt intervention. This
malignancy is humbling as cure is not rendered even with optimal
surgical resection.
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Table 1
Growth kinetics of the renal mass.
Post-operative Day Size (cm)
0 e operative specimen 14.3
46 10.6
51 13.5
56 14.6
80 21.5
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